Henry Fisher - Balancing Scientific Integrity, Business Viability, and Patient Outcomes

Psychedelic-assisted therapy trials face inherent challenges in balancing rigorous scientific integrity with the business pressures of clinical drug development. Commercial entities operating in this space must develop specialized trial networks that prioritize patient experience and non-clinical settings to optimize trial retention and data quality. Adaptive trial designs offer a viable strategy to manage these complexities, allowing for efficient, step-wise investigative procedures that minimize administrative and regulatory friction. Regulatory scrutiny, as evidenced by recent FDA rejection of MDMA-assisted therapy, highlights significant concerns regarding blinding, patient recruitment, and therapist-related misconduct. Addressing these issues requires standardized therapeutic protocols, the integration of AI for behavioral monitoring, and the use of independent research organizations to maintain necessary scientific distance and data reliability.